EU Looks At New Ways To Tackle Antibiotic Market Failure
Exclusivity Vouchers And Fee Waivers Under Consideration
Executive Summary
A novel Swedish payment scheme and transferable exclusivity vouchers for new antimicrobials are among mechanisms being examined by the European Commission for encouraging the development of new drugs to tackle the growing problem of antibiotic resistance.
You may also be interested in...
New AMR Report Is ‘A Wake-Up Call’, Says Industry Body
Another day, another report on how to tackle the ever-present problem of antimicrobial resistance and the dearth of new treatment. In its latest assessment of the state of play, the AMR Industry Alliance has come up with some alarming facts and figures – and some ideas for the next steps.
UK Plans Upfront Payment Scheme To Spur Antimicrobial Development
A new UK project will look at the potential of upfront payments to encourage companies to invest in the development of new antimicrobial drugs. The scheme, developed by NICE and NHS England, will use a tailored health technology assessment approach and is seen as a possible model for other countries to emulate in the fight against antimicrobial resistance.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.